E5531, a pure endotoxin antagonist of high potency

Science. 1995 Apr 7;268(5207):80-3. doi: 10.1126/science.7701344.

Abstract

Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.

MeSH terms

  • Animals
  • BCG Vaccine / immunology
  • Cytokines / metabolism
  • Drug Design
  • Endotoxins / antagonists & inhibitors*
  • Escherichia coli Infections / immunology
  • Gram-Negative Bacteria / immunology
  • Humans
  • In Vitro Techniques
  • Lipid A / analogs & derivatives*
  • Lipid A / chemical synthesis
  • Lipid A / chemistry
  • Lipid A / pharmacology
  • Lipopolysaccharides / antagonists & inhibitors
  • Macrophages / immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Monocytes / immunology
  • Moxalactam / pharmacology
  • Nitric Oxide / metabolism
  • Rhodobacter capsulatus / immunology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • BCG Vaccine
  • Cytokines
  • Endotoxins
  • Lipid A
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • E 5531
  • Moxalactam